Satiety Hormones

Satiety hormones are gastrointestinal peptides released from enteroendocrine cells in response to nutrient ingestion that signal meal termination (satiation) and maintain subsequent between-meal satiety. The principal satiety hormones are cholecystokinin (CCK), peptide YY (PYY), glucagon-like peptide 1 (GLP-1), oxyntomodulin, and amylin. Understanding satiety hormone physiology has driven both dietary recommendations (protein, fiber, meal composition) and pharmacological development (GLP-1 agonists).

Cholecystokinin (CCK)

CCK is released from duodenal and jejunal I-cells in response to dietary fat and protein in the small intestine. Its classical roles — gallbladder contraction and pancreatic enzyme secretion — position it for meal-size regulation: CCK slows gastric emptying and signals vagal afferents that transmit to the nucleus tractus solitarius of the brainstem. CCK has a short half-life (~5 minutes) and is most relevant to within-meal satiation rather than sustained between-meal satiety. Administration of CCK or CCK agonists reduces meal size in controlled studies.

Peptide YY (PYY)

PYY is co-secreted with GLP-1 from L-cells distributed along the ileum and colon in response to nutrient delivery. The active form PYY(3-36) inhibits appetite via Y2 receptors in the hypothalamic arcuate nucleus and signals via vagal pathways. PYY has a longer half-life than CCK (~60-90 minutes) and contributes to between-meal satiety. Batterham et al. (Nature 2002) demonstrated that PYY infusion reduces subsequent meal size in lean and obese subjects. Protein- and fat-rich meals are stronger PYY secretagogues than refined carbohydrate.

GLP-1 (glucagon-like peptide 1)

GLP-1 is co-secreted with PYY from L-cells. Beyond satiety effects, GLP-1 is the dominant incretin hormone, potentiating glucose-dependent insulin secretion from pancreatic beta-cells. Its satiety effects are mediated through central GLP-1 receptors (hypothalamus, brainstem), vagal pathways, and slowed gastric emptying. Native GLP-1 has a very short half-life (2 minutes) due to DPP-4 degradation, but GLP-1 receptor agonists (liraglutide, semaglutide, tirzepatide) that resist degradation have transformed obesity and type 2 diabetes treatment, producing 5-20% body weight reduction across phase III trials.

Oxyntomodulin

Oxyntomodulin is a proglucagon-derived peptide co-secreted with GLP-1 from L-cells. It activates both GLP-1 and glucagon receptors, producing a combination of appetite suppression (via GLP-1R) and increased energy expenditure (via glucagon receptor). Dual and triple agonists incorporating oxyntomodulin-like pharmacology are under active development for obesity.

Amylin

Amylin is co-secreted with insulin from pancreatic beta-cells in response to nutrient intake. It slows gastric emptying, suppresses glucagon, and contributes to meal-related satiety. Pramlintide, an amylin analogue, is used as adjunctive therapy in type 1 and type 2 diabetes.

Ghrelin — the counter-regulatory "hunger hormone"

Conceptually complementary to satiety hormones is ghrelin, released from gastric X/A-like cells during fasting and suppressed by food intake. Ghrelin is the principal peripheral orexigenic signal, promoting hunger and gastric motility. Postprandial ghrelin suppression is part of normal satiety physiology; blunted ghrelin suppression is observed in some obesity phenotypes.

Dietary modulation

Meal composition substantially influences satiety hormone release. Protein is the strongest macronutrient stimulus for CCK, PYY, and GLP-1 release, consistent with its high satiety efficiency (per-gram satiety ranking: protein > fiber > fat ≈ complex carb > simple sugar). Fiber — particularly viscous soluble fiber and fermentable fibers reaching the colon — produces sustained PYY and GLP-1 release, partly through colonic short-chain fatty acid generation. Fat produces substantial CCK release. Refined carbohydrate produces minimal and brief satiety hormone response, contributing to the lower per-calorie satiety of refined-carbohydrate-rich meals.

Pharmacological exploitation

The remarkable clinical efficacy of GLP-1 receptor agonists (semaglutide 2.4 mg for obesity, achieving ~15% weight loss at 68 weeks in STEP-1) represents the most successful pharmacological exploitation of satiety hormone physiology. Dual GIP/GLP-1 agonists (tirzepatide) and triple agonists in development achieve even greater weight reduction. These agents slow gastric emptying substantially, which also underlies some of their adverse effects (nausea, vomiting, delayed absorption of co-administered medications).

Dietary assessment implications

Meal-composition modeling in nutrition tracking should recognize that isocaloric meals differ substantially in their satiety signaling and consequent appetite regulation. Protein-first and fiber-rich meal patterns leverage endogenous satiety hormone physiology to support spontaneous energy intake regulation.